{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:17:06Z","timestamp":1793431026255,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T00:00:00Z","timestamp":1481760000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s12325-016-0457-8","type":"journal-article","created":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T13:40:56Z","timestamp":1481809256000},"page":"436-451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":124,"title":["Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus"],"prefix":"10.1007","volume":"34","author":[{"given":"Hiroyuki","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuko","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Togo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuya","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Kaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,15]]},"reference":[{"issue":"9922","key":"457_CR1","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/S0140-6736(13)62154-6","volume":"383","author":"SE Kahn","year":"2014","unstructured":"Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383(9922):1068\u201383.","journal-title":"Lancet"},{"issue":"2","key":"457_CR2","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","volume":"27","author":"JE Gerich","year":"2010","unstructured":"Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27(2):136\u201342.","journal-title":"Diabet Med"},{"issue":"1","key":"457_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1463-1326.2011.01511.x","volume":"14","author":"RA DeFronzo","year":"2012","unstructured":"DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14(1):5\u201314.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"457_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrendo.2011.243","volume":"8","author":"E Ferrannini","year":"2012","unstructured":"Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8(8):495\u2013502.","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"457_CR5","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.2337\/dc15-0642","volume":"38","author":"S Mudaliar","year":"2015","unstructured":"Mudaliar S, Polidori D, Zambrowicz B, Henry RR. Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care. 2015;38(12):2344\u201353.","journal-title":"Diabetes Care"},{"key":"457_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2147\/DMSO.S61438","volume":"7","author":"D Lorber","year":"2014","unstructured":"Lorber D. Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes, Metab Syndr Obes. 2014;7:169\u201383.","journal-title":"Diabetes, Metab Syndr Obes"},{"issue":"1","key":"457_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","volume":"75","author":"AJ Scheen","year":"2015","unstructured":"Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33\u201359.","journal-title":"Drugs"},{"issue":"3","key":"457_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/jdi.12214","volume":"5","author":"Y Fujita","year":"2014","unstructured":"Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. J Diabetes Investig. 2014;5(3):265\u201375.","journal-title":"J Diabetes Investig"},{"issue":"2","key":"457_CR9","doi-asserted-by":"publisher","first-page":"e009417","DOI":"10.1136\/bmjopen-2015-009417","volume":"6","author":"DS Shyangdan","year":"2016","unstructured":"Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2016;6(2):e009417.","journal-title":"BMJ Open"},{"issue":"212","key":"457_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ijcard.2016.02.134","volume":"1","author":"RK Ghosh","year":"2016","unstructured":"Ghosh RK, Bandyopadhyay D, Hajra A, Biswas M, Gupta A. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: a comprehensive review of clinical and preclinical studies. Int J Cardiol. 2016;1(212):29\u201336.","journal-title":"Int J Cardiol"},{"issue":"22","key":"457_CR11","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"19","key":"457_CR12","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","volume":"37","author":"D Fitchett","year":"2016","unstructured":"Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J. 2016;37(19):1526\u201334.","journal-title":"Eur Heart J"},{"issue":"1","key":"457_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12933-016-0403-8","volume":"15","author":"G Perseghin","year":"2016","unstructured":"Perseghin G, Solini A. The EMPA-REG outcome study: critical appraisal and potential clinical implications. Cardiovasc Diabetol. 2016;15(1):85.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"457_CR14","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1185\/03007995.2016.1161608","volume":"32","author":"KS Lam","year":"2016","unstructured":"Lam KS, Chow CC, Tan KC, Ma RC, Kong AP, Tong PC, et al. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes. Curr Med Res Opin. 2016;32(6):1097\u2013108.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"457_CR15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/jgs.14028","volume":"64","author":"AJ Sinclair","year":"2016","unstructured":"Sinclair AJ, Bode B, Harris S, Vijapurkar U, Shaw W, Desai M, et al. Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: a pooled analysis. J Am Geriatr Soc. 2016;64(3):543\u201352.","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"457_CR16","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s40265-014-0225-5","volume":"74","author":"GL Plosker","year":"2014","unstructured":"Plosker GL. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74(7):807\u201324.","journal-title":"Drugs"},{"key":"457_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/nyas.12852","volume":"1358","author":"N Rosenthal","year":"2015","unstructured":"Rosenthal N, Meininger G, Ways K, Polidori D, Desai M, Qiu R, et al. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci. 2015;1358:28\u201343.","journal-title":"Ann N Y Acad Sci"},{"key":"457_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2147\/DMSO.S90662","volume":"8","author":"J Seufert","year":"2015","unstructured":"Seufert J. SGLT2 inhibitors\u2014an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes Metab Syndr Obes. 2015;8:543\u201354.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"8","key":"457_CR19","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s12325-015-0234-0","volume":"32","author":"H Iijima","year":"2015","unstructured":"Iijima H, Kifuji T, Maruyama N, Inagaki N. Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Adv Ther. 2015;32(8):768\u201382.","journal-title":"Adv Ther"},{"issue":"9","key":"457_CR20","doi-asserted-by":"publisher","first-page":"e110069","DOI":"10.1371\/journal.pone.0106146","volume":"9","author":"S Sha","year":"2014","unstructured":"Sha S, Devineni D, Ghosh A, Polidori D, Hompesch M, Arnolds S, et al. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS One. 2014;9(9):e110069.","journal-title":"PLoS One"},{"issue":"4","key":"457_CR21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s12325-015-0200-x","volume":"32","author":"T Sasaki","year":"2015","unstructured":"Sasaki T, Seino Y, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Pharmacokinetics, pharmacodynamics, and safety of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, single-blind, placebo-controlled trial. Adv Ther. 2015;32(4):319\u201340.","journal-title":"Adv Ther"},{"issue":"7","key":"457_CR22","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/dom.12073","volume":"15","author":"T Heise","year":"2013","unstructured":"Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4\u00a0weeks\u2019 treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(7):613\u201321.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"457_CR23","doi-asserted-by":"publisher","first-page":"F1098","DOI":"10.1152\/ajprenal.00505.2014","volume":"308","author":"AM Weinstein","year":"2015","unstructured":"Weinstein AM. A mathematical model of the rat nephron: glucose transport. Am J Physiol Renal Physiol. 2015;308(10):F1098\u2013118.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"201","key":"457_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2015.07.072","volume":"15","author":"T Takeuchi","year":"2015","unstructured":"Takeuchi T, Dohi K, Omori T, Moriwaki K, Sato Y, Nakamori S, et al. Diuretic effects of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure. Int J Cardiol. 2015;15(201):1\u20133.","journal-title":"Int J Cardiol"},{"key":"457_CR25","volume-title":"Renal pathophysiology: the essentials","author":"H Rennke","year":"2014","unstructured":"Rennke H, Denker B. Renal pathophysiology: the essentials. 4th ed. Philadelphia: Wolters Kluwer\/Lippincott Williams & Wilkins; 2014.","edition":"4"},{"issue":"9","key":"457_CR26","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853\u201362.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"457_CR27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1042\/CS20070229","volume":"114","author":"J Piuhola","year":"2008","unstructured":"Piuhola J, Kerkela R, Keenan JI, Hampton MB, Richards AM, Pemberton CJ. Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia\/reperfusion injury. Clin Sci (Lond). 2008;114(4):293\u2013304.","journal-title":"Clin Sci (Lond)"},{"issue":"8","key":"457_CR28","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.2337\/dc12-2391","volume":"36","author":"D Polidori","year":"2013","unstructured":"Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36(8):2154\u201361.","journal-title":"Diabetes Care"},{"issue":"1","key":"457_CR29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1517\/17425255.2015.982531","volume":"11","author":"S Kinoshita","year":"2015","unstructured":"Kinoshita S, Kondo K. Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers. Expert Opin Drug Metab Toxicol. 2015;11(1):7\u201314.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"457_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","volume":"14","author":"R Grempler","year":"2012","unstructured":"Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14(1):83\u201390.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"457_CR31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1124\/jpet.115.225508","volume":"354","author":"T Oguma","year":"2015","unstructured":"Oguma T, Nakayama K, Kuriyama C, Matsushita Y, Yoshida K, Hikida K, et al. Intestinal sodium glucose cotransporter 1 inhibition enhances glucagon-like peptide-1 secretion in normal and diabetic rodents. J Pharmacol Exp Ther. 2015;354(3):279\u201389.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"457_CR32","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1517\/14656566.2015.1055250","volume":"16","author":"N Inagaki","year":"2015","unstructured":"Inagaki N, Goda M, Yokota S, Maruyama N, Iijima H. Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus: post hoc subgroup analyses according to body mass index in a 52-week open-label study. Expert Opin Pharmacother. 2015;16(11):1577\u201391.","journal-title":"Expert Opin Pharmacother"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0457-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-016-0457-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0457-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T18:51:01Z","timestamp":1548096661000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-016-0457-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,15]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["457"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0457-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,15]]},"assertion":[{"value":"6 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2016","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}